Tekna Holding Valuation
Is 8VB undervalued compared to its fair value, analyst forecasts and its price relative to the market?
Valuation Score
0/6Valuation Score 0/6
Below Fair Value
Significantly Below Fair Value
Price-To-Sales vs Peers
Price-To-Sales vs Industry
Price-To-Sales vs Fair Ratio
Analyst Forecast
Share Price vs Fair Value
What is the Fair Price of 8VB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.
Below Fair Value: Insufficient data to calculate 8VB's fair value for valuation analysis.
Significantly Below Fair Value: Insufficient data to calculate 8VB's fair value for valuation analysis.
Key Valuation Metric
Which metric is best to use when looking at relative valuation for 8VB?
Key metric: As 8VB is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.
| What is 8VB's PS Ratio? | |
|---|---|
| PS Ratio | 1.4x |
| Sales | CA$38.92m |
| Market Cap | CA$54.20m |
| Key Statistics | |
|---|---|
| Enterprise Value/Revenue | 2.1x |
| Enterprise Value/EBITDA | -7.3x |
| PEG Ratio | n/a |
Price to Sales Ratio vs Peers
How does 8VB's PS Ratio compare to its peers?
| Company | Forward PS | Estimated Growth | Market Cap |
|---|---|---|---|
| Peer Average | 0.7x | ||
BNN BRAIN Biotech | 1.1x | 8.5% | €63.4m |
2HRA H&R GmbH KGaA | 0.1x | 2.7% | €128.4m |
NTG Nabaltec | 0.6x | 4.5% | €120.1m |
BIG1 Bio-Gate | 0.9x | 16.3% | €6.5m |
8VB Tekna Holding | 1.4x | n/a | €427.0m |
Price-To-Sales vs Peers: 8VB is expensive based on its Price-To-Sales Ratio (1.4x) compared to the peer average (0.7x).
Price to Sales Ratio vs Industry
How does 8VB's PS Ratio compare vs other companies in the DE Chemicals Industry?
Price-To-Sales vs Industry: 8VB is expensive based on its Price-To-Sales Ratio (1.4x) compared to the European Chemicals industry average (1x).
Price to Sales Ratio vs Fair Ratio
What is 8VB's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.
| Fair Ratio | |
|---|---|
| Current PS Ratio | 1.4x |
| Fair PS Ratio | n/a |
Price-To-Sales vs Fair Ratio: Insufficient data to calculate 8VB's Price-To-Sales Fair Ratio for valuation analysis.
Analyst Price Targets
What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?
Analyst Forecast: Insufficient data to show price forecast.
Discover undervalued companies
Tokuyama
JP¥189.7b
Produces and sells various chemical products in Japan.
TBT
JP¥15.90
7D
-1.9%
1Y
12.0%
Central Asia Metals
UK£279.8m
Operates as a base metals producer.
9C3
UK£1.97
7D
3.1%
1Y
2.1%
Cabka
€64.2m
Manufactures and sells pallets and large containers made from recycled plastic in Europe, North America, and internationally.
7GW
€2.54
7D
0%
1Y
-63.2%